Australia's most trusted
source of pharma news
Saturday, 18 April 2026
Posted 16 April 2026 PM
Galderma’s Nemluvio, considered again at the PBAC’s meeting last month, is living up to the hype overseas, with the company doubling the drug’s peak sales projection to US$4 billion-plus.
Announcing the updated guidance in the company’s 2025 full-year financial results, Galderma CEO Flemming Ornskov described the launch trajectory of Nemluvio as “outstanding.”

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.